Friday, April 22, 2022 12:58:29 PM
NUVECTIS PHARMA (116%)
Founded in 2020 and headquartered in Fort Lee, N.J., it is a preclinical stage biopharmaceutical firm that focuses on novel targeted small molecule therapeutics for treating cancer. Nuvectis Pharma Inc (NASDAQ:NVCT) shares are up almost 28% in the last one month but are down almost 5% in the last five days. Its shares are currently trading over $9.50, giving it a market cap of over $120 million. Nuvectis Pharma went public in early February.
12.7 million shares (NVAC has 24.2 million shares)
52 week low was $3.08 (February 4), 52 week high was $11.04 (April 6, 2 months after it went public on February 4).
Now trading at $9.67 (April 22).
These opinions are my own and are not intended as investment advice. If you feel that my statements are "Pumping", Propaganda, or manipulative in any way, please refrain from trading and seek medical treatment immediately.
Recent NVAC News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/11/2024 01:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:32 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/28/2024 02:34:46 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 01/29/2024 01:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:00:10 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 01/16/2024 01:27:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:10:08 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/11/2023 11:10:15 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/01/2023 10:24:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:00:35 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 10/06/2023 08:29:23 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/13/2023 09:16:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 09:16:05 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 09/12/2023 09:19:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:00:37 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/21/2023 08:07:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM